Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-07

AUTHORS

Vanessa Buchanan, Will Sullivan, Chris Graham, LaStella Miles, Steffen Marc Jugl, Praveen Gunda, Anna Halliday, Bruce Kirkham

ABSTRACT

OBJECTIVE: The aim was to determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active psoriatic arthritis (PsA) who are tumour necrosis factor inhibitor (TNFi) naïve and without concomitant moderate-to-severe psoriasis, and who have responded inadequately to conventional systemic disease-modifying anti-rheumatic drugs (csDMARDs). PERSPECTIVE AND SETTING: The study took the perspective and setting of the UK National Health Service (NHS). METHODS: The model structure was a 3-month decision tree leading into a Markov model. Separate analyses based on the number of prior csDMARDs (one and two or more) were conducted, with secukinumab 150 mg compared to standard of care (SoC) and TNFis, respectively, for each subpopulation. Clinical parameters, including response at 3 months, were from the FUTURE 2 trial and a network meta-analysis. Outcomes included total costs and quality-adjusted life years (QALYs) over the 40-year time horizon (3.5% annual discount for both outcomes; cost year 2017), and incremental cost effectiveness ratios (ICERs). RESULTS: The ICER for secukinumab 150 mg versus SoC was £28,748 per QALY gained (one prior csDMARD). Secukinumab 150 mg dominated golimumab, certolizumab pegol and etanercept, and had an ICER of £5680 per QALY gained versus adalimumab and > £1 million saved per QALY foregone versus infliximab (two or more prior csDMARDs). Valuing one QALY at between £20,000 and £30,000, the probability of secukinumab having the highest net monetary benefit was 48.9% (one prior csDMARD) and 88.9% (two or more prior csDMARDs). Parameters related to Health Assessment Questionnaire scores were most influential. CONCLUSIONS: Secukinumab 150 mg at list price appears to represent a cost-effective use of NHS resources for adults with PsA who have responded inadequately to one or two or more prior csDMARDs. More... »

PAGES

867-878

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40273-018-0674-x

DOI

http://dx.doi.org/10.1007/s40273-018-0674-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1104169923

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29797187


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "BresMed", 
          "id": "https://www.grid.ac/institutes/grid.482857.4", 
          "name": [
            "BresMed Health Solutions, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Buchanan", 
        "givenName": "Vanessa", 
        "id": "sg:person.010253532660.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010253532660.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BresMed", 
          "id": "https://www.grid.ac/institutes/grid.482857.4", 
          "name": [
            "BresMed Health Solutions, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sullivan", 
        "givenName": "Will", 
        "id": "sg:person.0755323567.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755323567.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "RTI International", 
          "id": "https://www.grid.ac/institutes/grid.62562.35", 
          "name": [
            "RTI Health Solutions, Research Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Graham", 
        "givenName": "Chris", 
        "id": "sg:person.011016632446.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011016632446.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "RTI International", 
          "id": "https://www.grid.ac/institutes/grid.62562.35", 
          "name": [
            "RTI Health Solutions, Research Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miles", 
        "givenName": "LaStella", 
        "id": "sg:person.01225443552.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225443552.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jugl", 
        "givenName": "Steffen Marc", 
        "id": "sg:person.012612572155.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012612572155.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (India)", 
          "id": "https://www.grid.ac/institutes/grid.464975.d", 
          "name": [
            "Novartis Healthcare Private Limited, Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gunda", 
        "givenName": "Praveen", 
        "id": "sg:person.01064712533.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064712533.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.418607.c", 
          "name": [
            "Novartis Pharmaceuticals UK Limited, Camberley, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Halliday", 
        "givenName": "Anna", 
        "id": "sg:person.0615147233.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615147233.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "King's College London", 
          "id": "https://www.grid.ac/institutes/grid.13097.3c", 
          "name": [
            "Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, UK", 
            "King\u2019s College London, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kirkham", 
        "givenName": "Bruce", 
        "id": "sg:person.0656665525.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656665525.72"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1002/art.1780401021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000238671"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/ard.2004.032482", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002609767"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2011-201244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008678110"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2474-15-26", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011167965", 
          "https://doi.org/10.1186/1471-2474-15-26"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2014-206418", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013200417"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/ket187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013982606"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.34436", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014808247"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40273-015-0350-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016324684", 
          "https://doi.org/10.1007/s40273-015-0350-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2015-208337", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022767391"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jdermsci.2010.04.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023481451"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2013-203696", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029726499"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1412679", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035341201"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/14651858.cd008794.pub2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037802444"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(15)61134-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040399320"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/keq242", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045367100"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.c147", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050124565"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-014-0191-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052835422", 
          "https://doi.org/10.1007/s40265-014-0191-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-014-0191-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052835422", 
          "https://doi.org/10.1007/s40265-014-0191-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2016-eular.1716", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062759892"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2016-eular.1716", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062759892"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3310/hta15100", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071139223"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/13696998.2017.1384737", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091933859"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3310/hta21560", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092070762"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40273-018-0618-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101005767", 
          "https://doi.org/10.1007/s40273-018-0618-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40273-018-0618-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101005767", 
          "https://doi.org/10.1007/s40273-018-0618-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-07", 
    "datePublishedReg": "2018-07-01", 
    "description": "OBJECTIVE: The aim was to determine the cost\u00a0effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active psoriatic arthritis (PsA) who are tumour necrosis factor inhibitor (TNFi) na\u00efve and without concomitant moderate-to-severe psoriasis, and who\u00a0have responded inadequately to conventional systemic disease-modifying anti-rheumatic drugs (csDMARDs).\nPERSPECTIVE AND SETTING: The study took the perspective and setting of the UK National Health Service (NHS).\nMETHODS: The model structure was a 3-month decision tree leading into a Markov model. Separate analyses based on the\u00a0number of prior csDMARDs (one and\u2009 two or more) were conducted, with secukinumab 150\u00a0mg compared to standard of care (SoC) and TNFis, respectively, for each subpopulation. Clinical parameters, including response at 3\u00a0months, were from the FUTURE 2 trial and a network meta-analysis. Outcomes included total costs and quality-adjusted life years (QALYs) over the 40-year time horizon (3.5% annual discount for both outcomes; cost year 2017), and incremental cost effectiveness ratios (ICERs).\nRESULTS: The ICER for secukinumab 150\u00a0mg versus SoC was \u00a328,748 per QALY gained (one prior csDMARD). Secukinumab 150\u00a0mg dominated golimumab, certolizumab pegol and etanercept, and had an ICER of \u00a35680 per QALY gained versus adalimumab and\u2009>\u2009\u00a31 million saved per QALY foregone versus infliximab (two or more prior csDMARDs). Valuing one QALY at between \u00a320,000 and \u00a330,000, the probability of secukinumab having the highest net monetary benefit was 48.9% (one prior csDMARD) and 88.9% (two or more prior csDMARDs). Parameters related to Health Assessment Questionnaire scores were most influential.\nCONCLUSIONS: Secukinumab 150\u00a0mg at list price appears to represent a cost-effective use of NHS resources for adults with PsA who have responded inadequately to one or two or more prior csDMARDs.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40273-018-0674-x", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1102812", 
        "issn": [
          "1170-7690", 
          "1179-2027"
        ], 
        "name": "PharmacoEconomics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "36"
      }
    ], 
    "name": "Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK", 
    "pagination": "867-878", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "5b690a5c94828339f0b94637504f20285721ef4499d02f6c4d4a5e6fbfba7411"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29797187"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9212404"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40273-018-0674-x"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1104169923"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40273-018-0674-x", 
      "https://app.dimensions.ai/details/publication/pub.1104169923"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T02:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8700_00000604.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs40273-018-0674-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0674-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0674-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0674-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0674-x'


 

This table displays all metadata directly associated to this object as RDF triples.

204 TRIPLES      21 PREDICATES      51 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40273-018-0674-x schema:about anzsrc-for:14
2 anzsrc-for:1402
3 schema:author N7daad958f481428b943c2eb0b2b86031
4 schema:citation sg:pub.10.1007/s40265-014-0191-y
5 sg:pub.10.1007/s40273-015-0350-3
6 sg:pub.10.1007/s40273-018-0618-5
7 sg:pub.10.1186/1471-2474-15-26
8 https://doi.org/10.1002/14651858.cd008794.pub2
9 https://doi.org/10.1002/art.1780401021
10 https://doi.org/10.1002/art.34436
11 https://doi.org/10.1016/j.jdermsci.2010.04.014
12 https://doi.org/10.1016/s0140-6736(15)61134-5
13 https://doi.org/10.1056/nejmoa1412679
14 https://doi.org/10.1080/13696998.2017.1384737
15 https://doi.org/10.1093/rheumatology/keq242
16 https://doi.org/10.1093/rheumatology/ket187
17 https://doi.org/10.1136/annrheumdis-2011-201244
18 https://doi.org/10.1136/annrheumdis-2013-203696
19 https://doi.org/10.1136/annrheumdis-2014-206418
20 https://doi.org/10.1136/annrheumdis-2015-208337
21 https://doi.org/10.1136/annrheumdis-2016-eular.1716
22 https://doi.org/10.1136/ard.2004.032482
23 https://doi.org/10.1136/bmj.c147
24 https://doi.org/10.3310/hta15100
25 https://doi.org/10.3310/hta21560
26 schema:datePublished 2018-07
27 schema:datePublishedReg 2018-07-01
28 schema:description OBJECTIVE: The aim was to determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active psoriatic arthritis (PsA) who are tumour necrosis factor inhibitor (TNFi) naïve and without concomitant moderate-to-severe psoriasis, and who have responded inadequately to conventional systemic disease-modifying anti-rheumatic drugs (csDMARDs). PERSPECTIVE AND SETTING: The study took the perspective and setting of the UK National Health Service (NHS). METHODS: The model structure was a 3-month decision tree leading into a Markov model. Separate analyses based on the number of prior csDMARDs (one and  two or more) were conducted, with secukinumab 150 mg compared to standard of care (SoC) and TNFis, respectively, for each subpopulation. Clinical parameters, including response at 3 months, were from the FUTURE 2 trial and a network meta-analysis. Outcomes included total costs and quality-adjusted life years (QALYs) over the 40-year time horizon (3.5% annual discount for both outcomes; cost year 2017), and incremental cost effectiveness ratios (ICERs). RESULTS: The ICER for secukinumab 150 mg versus SoC was £28,748 per QALY gained (one prior csDMARD). Secukinumab 150 mg dominated golimumab, certolizumab pegol and etanercept, and had an ICER of £5680 per QALY gained versus adalimumab and > £1 million saved per QALY foregone versus infliximab (two or more prior csDMARDs). Valuing one QALY at between £20,000 and £30,000, the probability of secukinumab having the highest net monetary benefit was 48.9% (one prior csDMARD) and 88.9% (two or more prior csDMARDs). Parameters related to Health Assessment Questionnaire scores were most influential. CONCLUSIONS: Secukinumab 150 mg at list price appears to represent a cost-effective use of NHS resources for adults with PsA who have responded inadequately to one or two or more prior csDMARDs.
29 schema:genre research_article
30 schema:inLanguage en
31 schema:isAccessibleForFree true
32 schema:isPartOf N9644c591214a48b787e3c318176b8b03
33 Ndece84040c4649f0a74987a8aae0b1e0
34 sg:journal.1102812
35 schema:name Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
36 schema:pagination 867-878
37 schema:productId N0cc879cc4abe4375b273a673e62b1a89
38 N210bfaf2b4934e04a9e06f36c64d66dd
39 N52ca8db6340942f280e15749dd6b544e
40 N96e35b4934d84fc08ea64fb506376482
41 Nf7f8caf1c3c14938b11a944df8fcfc8c
42 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104169923
43 https://doi.org/10.1007/s40273-018-0674-x
44 schema:sdDatePublished 2019-04-11T02:32
45 schema:sdLicense https://scigraph.springernature.com/explorer/license/
46 schema:sdPublisher N09adf8e1a2fe4db29aed66d9953386e1
47 schema:url https://link.springer.com/10.1007%2Fs40273-018-0674-x
48 sgo:license sg:explorer/license/
49 sgo:sdDataset articles
50 rdf:type schema:ScholarlyArticle
51 N09adf8e1a2fe4db29aed66d9953386e1 schema:name Springer Nature - SN SciGraph project
52 rdf:type schema:Organization
53 N0cc879cc4abe4375b273a673e62b1a89 schema:name doi
54 schema:value 10.1007/s40273-018-0674-x
55 rdf:type schema:PropertyValue
56 N1e87b9d03b434c19a444ab6437ce528b rdf:first sg:person.0656665525.72
57 rdf:rest rdf:nil
58 N210bfaf2b4934e04a9e06f36c64d66dd schema:name pubmed_id
59 schema:value 29797187
60 rdf:type schema:PropertyValue
61 N52ca8db6340942f280e15749dd6b544e schema:name dimensions_id
62 schema:value pub.1104169923
63 rdf:type schema:PropertyValue
64 N781ab9088d3c4e68b15de5d61053da78 rdf:first sg:person.0615147233.96
65 rdf:rest N1e87b9d03b434c19a444ab6437ce528b
66 N7daad958f481428b943c2eb0b2b86031 rdf:first sg:person.010253532660.40
67 rdf:rest Na1b998fb900f41359c79dbc99d42a8a7
68 N9644c591214a48b787e3c318176b8b03 schema:issueNumber 7
69 rdf:type schema:PublicationIssue
70 N96e35b4934d84fc08ea64fb506376482 schema:name nlm_unique_id
71 schema:value 9212404
72 rdf:type schema:PropertyValue
73 Na1b998fb900f41359c79dbc99d42a8a7 rdf:first sg:person.0755323567.42
74 rdf:rest Ne6a29f0734524e2bb13076b9b7d64460
75 Nb4e77a8bd5a946e187563b443cb0ee85 rdf:first sg:person.012612572155.70
76 rdf:rest Ncf8f5bf8bc44451bb714f4fe9d08c791
77 Ncf8f5bf8bc44451bb714f4fe9d08c791 rdf:first sg:person.01064712533.04
78 rdf:rest N781ab9088d3c4e68b15de5d61053da78
79 Ndece84040c4649f0a74987a8aae0b1e0 schema:volumeNumber 36
80 rdf:type schema:PublicationVolume
81 Ne6a29f0734524e2bb13076b9b7d64460 rdf:first sg:person.011016632446.35
82 rdf:rest Neef7ffd52f6747818c3ee50b4dc63c92
83 Neef7ffd52f6747818c3ee50b4dc63c92 rdf:first sg:person.01225443552.51
84 rdf:rest Nb4e77a8bd5a946e187563b443cb0ee85
85 Nf7f8caf1c3c14938b11a944df8fcfc8c schema:name readcube_id
86 schema:value 5b690a5c94828339f0b94637504f20285721ef4499d02f6c4d4a5e6fbfba7411
87 rdf:type schema:PropertyValue
88 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
89 schema:name Economics
90 rdf:type schema:DefinedTerm
91 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
92 schema:name Applied Economics
93 rdf:type schema:DefinedTerm
94 sg:journal.1102812 schema:issn 1170-7690
95 1179-2027
96 schema:name PharmacoEconomics
97 rdf:type schema:Periodical
98 sg:person.010253532660.40 schema:affiliation https://www.grid.ac/institutes/grid.482857.4
99 schema:familyName Buchanan
100 schema:givenName Vanessa
101 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010253532660.40
102 rdf:type schema:Person
103 sg:person.01064712533.04 schema:affiliation https://www.grid.ac/institutes/grid.464975.d
104 schema:familyName Gunda
105 schema:givenName Praveen
106 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064712533.04
107 rdf:type schema:Person
108 sg:person.011016632446.35 schema:affiliation https://www.grid.ac/institutes/grid.62562.35
109 schema:familyName Graham
110 schema:givenName Chris
111 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011016632446.35
112 rdf:type schema:Person
113 sg:person.01225443552.51 schema:affiliation https://www.grid.ac/institutes/grid.62562.35
114 schema:familyName Miles
115 schema:givenName LaStella
116 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225443552.51
117 rdf:type schema:Person
118 sg:person.012612572155.70 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
119 schema:familyName Jugl
120 schema:givenName Steffen Marc
121 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012612572155.70
122 rdf:type schema:Person
123 sg:person.0615147233.96 schema:affiliation https://www.grid.ac/institutes/grid.418607.c
124 schema:familyName Halliday
125 schema:givenName Anna
126 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615147233.96
127 rdf:type schema:Person
128 sg:person.0656665525.72 schema:affiliation https://www.grid.ac/institutes/grid.13097.3c
129 schema:familyName Kirkham
130 schema:givenName Bruce
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656665525.72
132 rdf:type schema:Person
133 sg:person.0755323567.42 schema:affiliation https://www.grid.ac/institutes/grid.482857.4
134 schema:familyName Sullivan
135 schema:givenName Will
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755323567.42
137 rdf:type schema:Person
138 sg:pub.10.1007/s40265-014-0191-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1052835422
139 https://doi.org/10.1007/s40265-014-0191-y
140 rdf:type schema:CreativeWork
141 sg:pub.10.1007/s40273-015-0350-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016324684
142 https://doi.org/10.1007/s40273-015-0350-3
143 rdf:type schema:CreativeWork
144 sg:pub.10.1007/s40273-018-0618-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101005767
145 https://doi.org/10.1007/s40273-018-0618-5
146 rdf:type schema:CreativeWork
147 sg:pub.10.1186/1471-2474-15-26 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011167965
148 https://doi.org/10.1186/1471-2474-15-26
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1002/14651858.cd008794.pub2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037802444
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1002/art.1780401021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000238671
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1002/art.34436 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014808247
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1016/j.jdermsci.2010.04.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023481451
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1016/s0140-6736(15)61134-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040399320
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1056/nejmoa1412679 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035341201
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1080/13696998.2017.1384737 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091933859
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1093/rheumatology/keq242 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045367100
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1093/rheumatology/ket187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013982606
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1136/annrheumdis-2011-201244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008678110
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1136/annrheumdis-2013-203696 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029726499
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1136/annrheumdis-2014-206418 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013200417
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1136/annrheumdis-2015-208337 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022767391
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1136/annrheumdis-2016-eular.1716 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062759892
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1136/ard.2004.032482 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002609767
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1136/bmj.c147 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050124565
181 rdf:type schema:CreativeWork
182 https://doi.org/10.3310/hta15100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071139223
183 rdf:type schema:CreativeWork
184 https://doi.org/10.3310/hta21560 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092070762
185 rdf:type schema:CreativeWork
186 https://www.grid.ac/institutes/grid.13097.3c schema:alternateName King's College London
187 schema:name Guy’s and St Thomas’ NHS Foundation Trust, London, UK
188 King’s College London, London, UK
189 rdf:type schema:Organization
190 https://www.grid.ac/institutes/grid.418607.c schema:alternateName Novartis (United Kingdom)
191 schema:name Novartis Pharmaceuticals UK Limited, Camberley, UK
192 rdf:type schema:Organization
193 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
194 schema:name Novartis Pharma AG, Basel, Switzerland
195 rdf:type schema:Organization
196 https://www.grid.ac/institutes/grid.464975.d schema:alternateName Novartis (India)
197 schema:name Novartis Healthcare Private Limited, Hyderabad, India
198 rdf:type schema:Organization
199 https://www.grid.ac/institutes/grid.482857.4 schema:alternateName BresMed
200 schema:name BresMed Health Solutions, Sheffield, UK
201 rdf:type schema:Organization
202 https://www.grid.ac/institutes/grid.62562.35 schema:alternateName RTI International
203 schema:name RTI Health Solutions, Research Triangle Park, NC, USA
204 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...